Cantor Fitzgerald Forecasts TRVI FY2025 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Trevi Therapeutics in a report released on Tuesday, July 1st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($0.39) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Cantor Fitzgerald also issued estimates for Trevi Therapeutics' FY2026 earnings at ($0.47) EPS.

A number of other research analysts have also weighed in on TRVI. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Raymond James Financial raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price target for the company from $9.00 to $29.00 in a research report on Monday, March 10th. HC Wainwright began coverage on Trevi Therapeutics in a report on Wednesday, May 28th. They set a "buy" rating and a $21.00 price objective for the company. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Finally, Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Trevi Therapeutics has an average rating of "Buy" and a consensus price target of $20.88.

Trevi Therapeutics Trading Down 1.4%

NASDAQ TRVI traded down $0.08 during mid-day trading on Thursday, hitting $5.90. The company's stock had a trading volume of 993,025 shares, compared to its average volume of 1,425,886. The firm has a market capitalization of $691.54 million, a price-to-earnings ratio of -13.10 and a beta of 0.46. The company's 50 day simple moving average is $6.28 and its 200 day simple moving average is $5.41. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04.

Institutional Trading of Trevi Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. boosted its position in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics during the 4th quarter worth $49,000. Strs Ohio purchased a new position in shares of Trevi Therapeutics in the 1st quarter worth about $52,000. Squarepoint Ops LLC bought a new position in Trevi Therapeutics during the fourth quarter valued at about $58,000. Finally, Two Sigma Advisers LP bought a new position in Trevi Therapeutics during the fourth quarter valued at about $66,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.